Featured Research

from universities, journals, and other organizations

Alcohol Researchers Identify New Medication That Lessens Relapse Risk

Date:
September 1, 1999
Source:
NIH-National Institute On Alcohol Abuse And Alcoholism
Summary:
A study in the current Archives of General Psychiatry (Volume 56, pages 719-724) shows that nalmefene, an opioid antagonist that is not now commercially available in the oral form studied, is effective in preventing relapse to heavy drinking in alcohol dependent individuals.

A study in the current Archives of General Psychiatry (Volume 56, pages 719-724) shows that nalmefene, an opioid antagonist that is not now commercially available in the oral form studied, is effective in preventing relapse to heavy drinking in alcohol dependent individuals. Barbara J. Mason, Ph.D., and colleagues at the University of Miami School of Medicine found from a 12-week double-blind, placebo-controlled clinical trial that patients who received nalmefene were 2.4 times less likely to relapse to heavy drinking than those who received a placebo.

"This study again demonstrates the promise of pharmacologic agents to work with standard behavioral treatments in the treatment of alcoholism. Prospects for improving treatment outcome have never been better," said Enoch Gordis, M.D., Director, National Institute on Alcohol Abuse and Alcoholism, a component of the National Institutes of Health.

Naltrexone, another opioid antagonist that is selective for the mu receptor, was approved by the U.S. Food and Drug Administration in 1994 for use in alcoholism treatment. The newer nalmefene is a "universal" opioid antagonist that works on all opioid receptors.

Men and women aged 18-65 years who met Diagnostic and Statistical Manual, Third Edition, Revised criteria for alcohol dependence participated in the study. Dr. Mason and her colleagues randomly assigned 105 of the 162 individuals screened to oral nalmefene at a dose of either 20 mg or 80 mg per day, or to placebo. All patients received professionally delivered, manual-guided, cognitive-behavioral therapy designed to increase their ability to avoid or cope with high-risk situations that can precipitate drinking.

The researchers found no significant differences between the 20 mg and 80 mg nalmefene groups and, therefore, presented their results as nalmefene versus placebo comparisons. Although one-third of the nalmefene patients relapsed to heavy drinking at least once during the 12-week trial, significantly more nalmefene than placebo patients altogether avoided relapse. Of patients who relapsed, those on nalmefene had fewer subsequent heavy-drinking episodes. Patients on nalmefene showed no evidence of medically serious adverse drug experiences and had high rates of medication compliance and treatment completion. The nalmefene and placebo groups did not differ in rates of abstinent days or self-reported craving severity.

"Alcohol consumption is mediated by multiple neurotransmitters and neuromodulators, including nonopioid systems, so that an opioid antagonist alone would not necessarily eliminate alcohol drinking in all alcohol dependent persons," said Dr. Mason. "But any agent that can reduce relapse would be a useful addition in treating alcoholic patients, approximately one-half of whom relapse within the first few months of most behavioral treatments." Several pharmaceutical companies have approached the University of Miami to review the nalmefene data in support of a new drug application to the FDA, Dr. Mason said.

"As neuroscience research advances knowledge of how alcohol acts on the brain, that knowledge will continue to be applied to develop new medications," said Richard Fuller, M.D., Director, Division of Clinical and Prevention Research, NIAAA. "Medications development is a top NIAAA priority."

"A Double-Blind, Placebo-Controlled Study of Oral Nalmefene for Alcohol Dependence" was conducted at the University of Miami School of Medicine Alcohol Disorders Research Clinic, Jackson Memorial Medical Center, Miami, Florida, with support from NIAAA. Through grants to researchers in medical and academic institutions, NIAAA supports an estimated 90 percent of alcohol research conducted in the United States.


Story Source:

The above story is based on materials provided by NIH-National Institute On Alcohol Abuse And Alcoholism. Note: Materials may be edited for content and length.


Cite This Page:

NIH-National Institute On Alcohol Abuse And Alcoholism. "Alcohol Researchers Identify New Medication That Lessens Relapse Risk." ScienceDaily. ScienceDaily, 1 September 1999. <www.sciencedaily.com/releases/1999/09/990901075829.htm>.
NIH-National Institute On Alcohol Abuse And Alcoholism. (1999, September 1). Alcohol Researchers Identify New Medication That Lessens Relapse Risk. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/1999/09/990901075829.htm
NIH-National Institute On Alcohol Abuse And Alcoholism. "Alcohol Researchers Identify New Medication That Lessens Relapse Risk." ScienceDaily. www.sciencedaily.com/releases/1999/09/990901075829.htm (accessed October 2, 2014).

Share This



More Mind & Brain News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Stopping School Violence

Stopping School Violence

Ivanhoe (Oct. 1, 2014) A trauma doctor steps out of the hospital and into the classroom to teach kids how to calmly solve conflicts, avoiding a trip to the ER. Video provided by Ivanhoe
Powered by NewsLook.com
Pineal Cysts: Debilitating Pain

Pineal Cysts: Debilitating Pain

Ivanhoe (Oct. 1, 2014) A tiny cyst in the brain that can cause debilitating symptoms like chronic headaches and insomnia, and the doctor who performs the delicate surgery to remove them. Video provided by Ivanhoe
Powered by NewsLook.com
Burning Away Brain Tumors

Burning Away Brain Tumors

Ivanhoe (Oct. 1, 2014) Doctors are 'cooking' brain tumors. Hear how this new laser-heat procedure cuts down on recovery time. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins